Turmeric and Curcumin

Turmeric in traditional medicine

Turmeric is the rhizome of Curcuma longa, a plant of the ginger family that serves as both a cooking spice and a traditional remedy. A 2026 review in Nutrients states that turmeric has a long history of use in traditional medical systems, particularly Indian Ayurveda and Chinese traditional medicine, where it has been used mainly for anti-inflammatory, pain-relieving and wound-related purposes. In Ayurveda, the review says, it is regarded as a remedy for digestive disorders, arthritis, skin diseases and inflammatory conditions.

The National Center for Complementary and Integrative Health (NCCIH) lists Chinese, Indian (Ayurvedic), Islamic and Thai medicine among the systems that have used turmeric, for complaints such as indigestion, colds, skin infections, arthritis, abdominal pain and liver disease. The sources reviewed for this page do not provide dated primary-source histories, so no claim is made here about how many centuries turmeric has been used.

From spice to extracted compound

Curcumin is one constituent of turmeric. Medicinal chemists writing in the Journal of Medicinal Chemistry in 2017 describe it as making up up to about 5 percent of the plant material, and say that the relative ease of isolating curcuminoids led to extensive study, including more than 120 clinical trials by their count and a published literature of more than 15,000 manuscripts on curcumin. Isolated curcumin, they note, is almost always a mixture of curcuminoids.

The modern supplement market

Because curcumin dissolves poorly and is absorbed poorly when swallowed, a research and product literature has grown around ways to raise its absorption. A 2023 review lists co-administration with piperine (a compound from black pepper), micelles, emulsions, nanoparticles, liposomes, solid dispersions, spray drying and complexes with galactomannosides among the approaches studied. The review does not date when each product type reached the market.

Case reports of liver injury linked to turmeric products in the United States Drug-Induced Liver Injury Network were all enrolled from 2011 onward, with six since 2017. The authors suggest this may reflect usage patterns or increased combination of turmeric with black pepper, which is one indicator of changing supplement use rather than a measure of sales.

Turmeric, curcumin and curcuminoids

In this literature turmeric usually means the rhizome or its powder, curcuminoids means the group of yellow compounds in it, and curcumin means the best-known member of that group. The terms are used loosely in trials and marketing. NCCIH notes that curcumin content varies by product, which makes studies hard to compare, and that some products add piperine to improve absorption.

What bioavailable means here

Products described as bioavailable or high-bioavailability are formulations designed to raise how much curcumin reaches the bloodstream, such as piperine combinations or liposomal and nanoparticle preparations. The Tuscan hepatitis series uses the phrase high bioavailability for the products it examined. None of the sources reviewed sets a standard threshold for the term, and a trial of one formulation cannot be assumed to apply to another.

Related Machipedia pages

This page is a member of the Herbal Medicine family page on Machipedia, which covers plant-based remedies in general and is not repeated here. Turmeric also appears in the pages on Ayurveda, Ayurvedic Herbal Medicine and Ayurvedic Diet, in discussions of an Anti-Inflammatory Diet, and under Dietary Supplements, where product content and quality are discussed. NCCIH treats culinary turmeric and supplement products as distinct categories of exposure.

Spice and traditional remedy

Turmeric is used as a food spice and as a traditional remedy. The sources reviewed describe the traditional uses in general terms and do not give preparation methods, so none are described here. A clinical-trial literature on supplements is largely separate from culinary use: a 2025 review of metabolic trials notes that the included studies primarily assessed standardized oral supplements and bioavailability-enhanced formulations rather than whole culinary turmeric.

Supplement and topical products

NCCIH describes oral turmeric and curcumin products, topical curcumin ointment studied for knee pain, and oral or mouthwash forms studied for mouth sores during cancer treatment. Content differs between products, and some include piperine. Reviews of formulation research describe liposomal, micellar, nanoparticle and other preparations. This page gives no amounts or product recommendations.

In the US Drug-Induced Liver Injury Network series, laboratory analysis confirmed turmeric in all seven products that could be tested, and three of the seven also contained piperine, which shows that products implicated in harm included both single-ingredient and piperine combination forms.

Uses in traditional systems

Traditional systems are reported to have used turmeric for digestive disorders, arthritis, skin diseases, wound care and inflammatory conditions in Ayurveda, and in Chinese medicine for anti-inflammatory and pain-related purposes. NCCIH adds indigestion, colds, skin infections, abdominal pain and liver disease across Indian, Chinese, Islamic and Thai traditions. These are descriptions of what traditions hold, not findings from controlled trials.

Uses promoted today

NCCIH states that turmeric is promoted today as a supplement for osteoarthritis, depression, allergies, itching and high cholesterol. Published reviews also frame curcumin as a candidate for metabolic conditions and for cancer chemoprevention, while stating that low bioavailability and limited therapeutic efficacy remain challenges. Promotion by sellers is not evidence of effect, and the evidence for each use is set out in the next section.

Osteoarthritis and joint pain

A 2016 systematic review of eight randomized trials reported lower pain scores and lower WOMAC scores with turmeric or curcumin than with placebo, and no significant difference in pain score against pain medicine across five studies. The authors state that the number of trials, the sample size and the methodological quality were not enough to draw definitive conclusions.

A 2022 meta-analysis of 15 trials with 1,670 people with knee osteoarthritis found curcuminoids alone more effective than placebo for pain and function and not inferior to anti-inflammatory drugs, but the authors cite low quality and substantial heterogeneity and call for cautious recommendation. A 2021 meta-analysis of 10 placebo-controlled trials with 783 patients reported better pain relief and function, also with heterogeneity. NCCIH calls the initial evidence positive and says higher-quality evidence is needed.

Ulcerative colitis

A 2022 meta-analysis of six randomized trials with 385 participants examined curcumin added to standard ulcerative colitis treatment. It reported a higher rate of clinical remission (relative risk 2.10, 95% confidence interval 1.13 to 3.89), but no clear difference in clinical improvement, endoscopic remission or endoscopic improvement.

A 2025 meta-analysis of 13 placebo-controlled trials in inflammatory bowel disease, mostly in ulcerative colitis, reported benefit for clinical remission and response in ulcerative colitis, with heterogeneity, and no superiority over placebo in Crohn disease.

Depression and anxiety

A 2025 systematic review of 15 randomized trials with 1,123 adults reported a statistically significant reduction in depressive symptoms (standardized mean difference -0.65) and anxiety symptoms among people whose mood symptoms accompanied chronic disease, with very high heterogeneity (I-squared 93 percent for depression). The authors urge caution because of heterogeneity, varying formulations and possible publication bias.

A 2026 review of 26 trials with 1,491 participants likewise reported lower symptom scores than placebo, and judged the certainty of the evidence moderate to low with substantial between-study heterogeneity.

Metabolic syndrome and related conditions

A 2025 meta-analysis of 104 randomized trials in adults with metabolic syndrome or related conditions reported pooled reductions in fasting blood sugar and HbA1c in type 2 diabetes, lower triglycerides and LDL cholesterol, and lower inflammatory markers, with moderate-to-high heterogeneity. The authors call for larger, long-term trials.

Cancer

A 2025 systematic review of plant extracts for oral squamous cell carcinoma included 12 laboratory and animal studies, among them turmeric and curcumin, and states that clinical trials in humans are necessary to confirm efficacy and safety. A 2026 review describes interest in curcumin for cancer chemoprevention and says low bioavailability and limited efficacy are unresolved. The sources reviewed contain no human trial showing that curcumin or turmeric prevents cancer.

The medicinal chemistry critique

Nelson and colleagues argued in 2017 that curcumin has been classified as both a pan-assay interference compound (PAINS) and an invalid metabolic panacea (IMPS). They state that curcumin is an unstable, reactive, poorly absorbed compound and therefore a highly improbable drug lead, and that to their knowledge it had not been conclusively effective in a randomized, placebo-controlled trial for any indication. This is the position of those authors as of 2017.

The same authors report that in the clinical studies they reviewed, curcumin could not be detected in the blood of most participants, and they propose that future work consider the chemical complexity of turmeric as a whole rather than isolated curcumin. Later meta-analyses cited above reach more favorable conclusions for some outcomes while describing low quality, so the sources disagree on how to interpret the trial results.

Trial quality and product differences

Across the reviews, authors repeatedly report small trials, heterogeneity and differences in formulation, dose and duration. NCCIH notes that curcumin content varies by product, which means a result for one product may not carry over to another. Reviews of reformulated products describe improved absorption in some studies, but absorption is not the same as clinical benefit.

Liver injury

A case series from the US Drug-Induced Liver Injury Network identified 10 turmeric-associated liver injury cases (2004 to 2022): 8 women, median age 56, injury mostly hepatocellular. Five people were hospitalized and one died of acute liver failure. Seven carried the immune gene variant HLA-B*35:01, at an allele frequency of 0.450 against 0.056 to 0.069 in population controls, and latency was 1 to 4 months. Authors state that turmeric can cause potentially severe liver injury.

A report from Tuscany described seven acute hepatitis cases from the Italian Phytovigilance system, all linked to formulations with high bioavailability and high curcuminoid content, and a systematic review of 23 other case reports, most of whom took other medicines too. This page describes the Italian reports only through that published series. These designs cannot establish how often injury occurs. NCCIH advises stopping use and contacting a provider for symptoms such as jaundice or dark urine.

Other effects and interactions

NCCIH lists nausea, vomiting, acid reflux, stomach upset, diarrhea and constipation as possible effects of oral products, hives or itching with topical use, and says supplement use in pregnancy may carry risk. A 2026 review advises that interactions with anticoagulants, antiplatelet agents and drugs processed by cytochrome P450 enzymes should be considered carefully. NCCIH names no specific drugs, and the sources reviewed do not address gallbladder or bile duct obstruction.

Lead chromate in turmeric spice

A 2019 study across Bangladesh found evidence of lead chromate yellow pigment added to turmeric roots during polishing in 7 of 9 major producing districts, with turmeric powder lead concentrations up to 1,152 micrograms per gram. Wholesalers reported the practice began more than 30 years ago and was driven by demand for bright yellow color, and polishers were reported to be unaware of the pigment's neurotoxic effects. The authors describe it as a public health problem.

A 2022 study states that lead adulteration of spices, mainly with lead chromate, has been documented globally. It compared portable X-ray fluorescence and a simple color test with laboratory mass spectrometry, finding close agreement for spice powders with the portable device, while the color test detected lead only at high concentrations and missed a spice-salt mixture. The sources reviewed do not report the lead content of supplements.

Who should ask a clinician

Based on the sources reviewed, people with liver disease or liver symptoms, those who take anticoagulants, antiplatelet drugs or other prescribed medicines, and those who are pregnant are groups for whom a clinician or pharmacist is the appropriate source of advice. Curcumin in the ulcerative colitis trials was added to standard treatment. Supplements should not delay or replace necessary medical care.